Literature DB >> 8821521

Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial.

D Parent1, M Bossens, D Bayot, C Kirkpatrick, F Graf, F E Wilkinson, R R Kaiser.   

Abstract

The efficacy of vaginal tablets (Gynoflor) containing 50 mg of a lyophilisate of viable, H2O2-producing Lactobacillus acidophilus (at least 10(7) colony forming units/tablet) and 0.03 mg estriol (CAS 50-27-1) for the treatment of bacterial vaginosis (BV) was tested in a multicentric, randomised, placebo-controlled clinical trial with parallel-group design. 32 non-menopausal women with positive diagnoses for BV, including intermediate cases, participated in the trial. Patients were diagnosed using the classical clinical parameters of BV according to Amsel and using microscopic analysis of the Gram-stained vaginal smear. A positive clinical diagnosis of BV required at least 2 of the following 4 clinical criteria to be positive; greyish-white, homogeneous leukorrhea; vaginal pH > 4.5; KOH test for volatile amines; presence of clue cells. Microscopic diagnosis of BV, on the other hand, was obtained if examination of the Gram-stained vaginal smear showed less than 6 lactobacilli per field of view (1000 x magnification). This corresponds to another definition of BV as "lactobacilli deficiency syndrome". The efficacy of the 6-day therapy with 1-2 vaginal tablets daily was evaluated using both clinical and microscopic analysis. Using Amsel's classical clinical parameters of BV, the cure rate (defined as < or = 1 of the 4 clinical criteria positive) two weeks after the start of therapy was 77% in the verum group and 25% in the placebo group. Four weeks after the start of therapy, the cure rate was 88% in the verum group and 22% in the placebo group. At both control examinations, the cure rate for the test group was significantly higher than that for the placebo group (p < 0.05, Fisher's exact test, 2-sided, significance level 0.05). In addition, the trial showed that after 6 days of treatment with the test preparation, the lactobacilli were capable of recolonising the vagina. A significant increase in the number of lactobacilli was observed in the Gram-stained vaginal smear for the patient group treated with the test preparation compared to the placebo patient group (p < 0.05, Fisher's exact test, 2-sided, significance level 0.05), two and four weeks after the start of the 6-day treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821521

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  13 in total

1.  Recurrent Bacterial Vaginosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

Review 2.  Exploring a road map to counter misconceptions about the cervicovaginal microbiome and disease.

Authors:  Jean M Macklaim; Craig R Cohen; Gilbert Donders; Gregory B Gloor; Janet E Hill; Groesbeck P Parham; Jacques Ravel; Gregory Spear; Janneke van de Wijgert; Gregor Reid
Journal:  Reprod Sci       Date:  2012-05-21       Impact factor: 3.060

3.  Sustained delivery of commensal bacteria from pod-intravaginal rings.

Authors:  Manjula Gunawardana; Madeline Mullen; Jennifer Yoo; Paul Webster; John A Moss; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

4.  Impact of Probiotic SYNBIO(®) Administered by Vaginal Suppositories in Promoting Vaginal Health of Apparently Healthy Women.

Authors:  Maria Cristina Verdenelli; Cinzia Cecchini; Maria Magdalena Coman; Stefania Silvi; Carla Orpianesi; Giuliana Coata; Alberto Cresci; Gian Carlo Di Renzo
Journal:  Curr Microbiol       Date:  2016-06-21       Impact factor: 2.188

5.  Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification.

Authors:  E R Boskey; K M Telsch; K J Whaley; T R Moench; R A Cone
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

Review 6.  Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review.

Authors:  Cihat Unlü; Gilbert Donders
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-12-01

7.  Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection.

Authors:  Susanna Cunningham-Rundles; Siv Ahrné; Rosemary Johann-Liang; Rachel Abuav; Ann-Margaret Dunn-Navarra; Claudia Grassey; Stig Bengmark; Joseph S Cervia
Journal:  Nutrients       Date:  2011-12-19       Impact factor: 5.717

8.  Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.

Authors:  Catriona S Bradshaw; Marie Pirotta; Deborah De Guingand; Jane S Hocking; Anna N Morton; Suzanne M Garland; Glenda Fehler; Andrea Morrow; Sandra Walker; Lenka A Vodstrcil; Christopher K Fairley
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

Review 9.  Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health.

Authors:  Mariya I Petrova; Elke Lievens; Shweta Malik; Nicole Imholz; Sarah Lebeer
Journal:  Front Physiol       Date:  2015-03-25       Impact factor: 4.566

Review 10.  Probiotics to counteract biofilm-associated infections: promising and conflicting data.

Authors:  Claudia Vuotto; Francesca Longo; Gianfranco Donelli
Journal:  Int J Oral Sci       Date:  2014-09-26       Impact factor: 6.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.